tbuckley/cabot-search huggingface dataset:
Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, December 2023
Authors: Hannah E. Reses, Heather Dubendris, Lori Haas, Kira Barbre, Sushmitha Ananth, Theresa Rowe, Elizabeth Mothershed, Elisha Hall, Ryan E. Wiegand, Megan C. Lindley, Sarah Meyer, Suchita A. Patel, Andrea Benin, Seth Kroop, Arjun Srinivasan, Jeneita M. Bell
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Nursing home residents are at risk for becoming infected with and experiencing severe complications from respiratory viruses, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV). Fall 2023 is the first season during which vaccines are simultaneously available to protect older adults in the United States against all three of these respiratory viruses. Nursing homes are required to report COVID-19 vaccination coverage and can voluntarily report influenza and RSV vaccination coverage among residents to CDC's National Healthcare Safety Network. The purpose of this study was to assess COVID-19, influenza, and RSV vaccination coverage among nursing home residents during the current 2023-24 respiratory virus season. As of December 10, 2023, 33.1% of nursing home residents were up to date with vaccination against COVID-19. Among residents at 20.2% and 19.4% of facilities that elected to report, coverage with influenza and RSV vaccines was 72.0% and 9.8%, respectively. Vaccination varied by U.S. Department of Health and Human Services region, social vulnerability index level, and facility size. There is an urgent need to protect nursing home residents against severe outcomes of respiratory illnesses by continuing efforts to increase vaccination against COVID-19 and influenza and discussing vaccination against RSV with eligible residents during the ongoing 2023-24 respiratory virus season.
The impact of multidisciplinary cancer conferences on overall survival: a meta-analysis
Authors: Ryan S Huang, Andrew Mihalache, Abdulwadud Nafees, Asad Hasan, Xiang Y Ye, Zhihui Liu, Natasha B Leighl, Srinivas Raman
Journal: JNCI Journal of the National Cancer Institute (2023)

Multidisciplinary cancer conferences consist of regular meetings between diverse specialists working together to share clinical decision making in cancer care. The aim of this study was to systematically review and meta-analyze the effect of multidisciplinary cancer conference intervention on the overall survival of patients with cancer.
Classifying and clustering mood disorder patients using smartphone data from a feasibility study
Authors: Carsten Langholm, Scott Breitinger, Lucy Gray, Fernando Goes, Alex Walker, Ashley Xiong, Cindy Stopel, Peter Zandi, Mark A. Frye, John Torous
Journal: npj Digital Medicine (2023)

Abstract Differentiating between bipolar disorder and major depressive disorder can be challenging for clinicians. The diagnostic process might benefit from new ways of monitoring the phenotypes of these disorders. Smartphone data might offer insight in this regard. Today, smartphones collect dense, multimodal data from which behavioral metrics can be derived. Distinct patterns in these metrics have the potential to differentiate the two conditions. To examine the feasibility of smartphone-based phenotyping, two study sites (Mayo Clinic, Johns Hopkins University) recruited patients with bipolar I disorder (BPI), bipolar II disorder (BPII), major depressive disorder (MDD), and undiagnosed controls for a 12-week observational study. On their smartphones, study participants used a digital phenotyping app (mindLAMP) for data collection. While in use, mindLAMP gathered real-time geolocation, accelerometer, and screen-state (on/off) data. mindLAMP was also used for EMA delivery. MindLAMP data was then used as input variables in binary classification, three-group k-nearest neighbors (KNN) classification, and k-means clustering. The best-performing binary classification model was able to classify patients as control or non-control with an AUC of 0.91 (random forest). The model that performed best at classifying patients as having MDD or bipolar I/II had an AUC of 0.62 (logistic regression). The k-means clustering model had a silhouette score of 0.46 and an ARI of 0.27. Results support the potential for digital phenotyping methods to cluster depression, bipolar disorder, and healthy controls. However, due to inconsistencies in accuracy, more data streams are required before these methods can be applied to clinical practice.
How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users’ guide
Authors: Kim S Thomas, Laura Howells, Yael A Leshem, Eric L Simpson, Christian Apfelbacher, Phyllis I Spuls, Louise A A Gerbens, Michael E Jacobson, Norito Katoh, Hywel C Williams, Beth L Stuart
Journal: British Journal of Dermatology (2023)

The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed upon the Core Outcome Set (COS) for use in atopic dermatitis (AD) clinical trials, but additional guidance is needed to maximize its uptake.
Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults — United States, Fall 2023
Authors: Carla L. Black, Jennifer L. Kriss, Hilda Razzaghi, Suchita A. Patel, Tammy A. Santibanez, Mehreen Meghani, Ashley Tippins, Shannon Stokley, Kevin Chatham-Stephens, Nicole F. Dowling, Georgina Peacock, James A. Singleton
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

During the 2023-24 respiratory virus season, the Advisory Committee on Immunization Practices recommends influenza and COVID-19 vaccines for all persons aged ≥6 months, and respiratory syncytial virus (RSV) vaccine is recommended for persons aged ≥60 years (using shared clinical decision-making), and for pregnant persons. Data from the National Immunization Survey-Adult COVID Module, a random-digit-dialed cellular telephone survey of U.S. adults aged ≥18 years, are used to monitor influenza, COVID-19, and RSV vaccination coverage. By December 9, 2023, an estimated 42.2% and 18.3% of adults aged ≥18 years reported receiving an influenza and updated 2023-2024 COVID-19 vaccine, respectively; 17.0% of adults aged ≥60 years had received RSV vaccine. Coverage varied by demographic characteristics. Overall, approximately 27% and 41% of adults aged ≥18 years and 53% of adults aged ≥60 years reported that they definitely or probably will be vaccinated or were unsure whether they would be vaccinated against influenza, COVID-19, and RSV, respectively. Strong provider recommendations for and offers of vaccination could increase influenza, COVID-19, and RSV vaccination coverage. Immunization programs and vaccination partners are encouraged to use these data to understand vaccination patterns and attitudes toward vaccination in their jurisdictions to guide planning, implementation, strengthening, and evaluation of vaccination activities.
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
Authors: Patrick R. Harrington, Jie Cong, Stephanie B. Troy, Jonathan M.O. Rawson, Julian J. O’Rear, Thamban Illath Valappil, Sarah McGarry Connelly, John Farley, Debra Birnkrant
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Rebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of nirmatrelvir/ritonavir to COVID-19 rebound remains unclear because most reports are based on individual cases or nonrandomized studies. Viral RNA shedding data from two phase 2/3, randomized, double-blind, placebo-controlled clinical trials of nirmatrelvir/ritonavir (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients [EPIC-HR] and Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients [EPIC-SR]) were analyzed to investigate the role of nirmatrelvir/ritonavir treatment in COVID-19 rebound. Rates of rebound of SARS-CoV-2 RNA shedding, identified based on an increase in nasopharyngeal viral RNA levels from day 5 (end-of-treatment) to day 10 or day 14, were similar between nirmatrelvir/ritonavir and placebo recipients. Among subjects with a virologic response through day 5, viral RNA rebound occurred in 6.4%-8.4% of nirmatrelvir/ritonavir recipients and 5.9%-6.5% of placebo recipients across EPIC-HR and the 2021/pre-Omicron and 2022/Omicron enrollment periods of EPIC-SR. Viral RNA rebound after nirmatrelvir/ritonavir treatment was not associated with COVID-19-related hospitalization or death. Data from randomized trials demonstrated that SARS-CoV-2 rebound can occur with or without antiviral treatment, supporting the Food and Drug Administration's determination of safety and efficacy of nirmatrelvir/ritonavir in eligible patients at high risk for severe COVID-19.
Reply to Wang et al.
Authors: Kien Vu Trung, Marcus Hollenbach
Journal: Endoscopy (2023)

Letter to: Comments on “Endoscopic papillectomy for ampullary lesions in patients with familial adenomatous polyposis compared with sporadic lesions: a propensity score-matched cohort”Endoscopy 2024; 56(01): 82-83DOI: 10.1055/a-2182-6101
Reply to Eleuteri <i>et al.</i>: High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure: Need for Patient Phenotyping?
Authors: Naman S. Shetty, Mokshad Gaonkar, Valentina Giammatteo, Pankaj Arora, Lorenzo Berra
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Reply to: High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure: Need for Patient Phenotyping?." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1
Authors: Carlos G Romo, Kavita Y Sarin, Jaishri O Blakeley
Journal: British Journal of Dermatology (2023)

Journal Article Corrected proof Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1 Get access Carlos G Romo, Carlos G Romo Conceptualization, Writing - original draft, Writing - review & editing Department of Neurology, Johns Hopkins University, Baltimore, MD Search for other works by this author on: Oxford Academic Google Scholar Kavita Y Sarin, Kavita Y Sarin Conceptualization, Writing - original draft, Writing - review & editing Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA Search for other works by this author on: Oxford Academic Google Scholar Jaishri O Blakeley Jaishri O Blakeley Conceptualization, Writing - original draft, Writing - review & editing Department of Neurology, Johns Hopkins University, Baltimore, MD Correspondence: Jaishri O. Blakeley. Email: jblakel3@jhmi.edu https://orcid.org/0000-0002-1049-0993 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad452, https://doi.org/10.1093/bjd/ljad452 Published: 20 December 2023 Article history Received: 03 November 2023 Revision received: 08 November 2023 Corrected and typeset: 20 December 2023 Published: 20 December 2023
The Molecular Biology of Midgut Neuroendocrine Neoplasms
Authors: Amy P Webster, Chrissie Thirlwell
Journal: Endocrine Reviews (2023)

Abstract Midgut neuroendocrine neoplasms (NENs) are one of the most common subtypes of NEN, and their incidence is rising globally. Despite being the most frequently diagnosed malignancy of the small intestine, little is known about their underlying molecular biology. Their unusually low mutational burden compared to other solid tumors and the unexplained occurrence of multifocal tumors makes the molecular biology of midgut NENs a particularly fascinating field of research. This review provides an overview of recent advances in the understanding of the interplay of the genetic, epigenetic, and transcriptomic landscape in the development of midgut NENs, a topic that is critical to understanding their biology and improving treatment options and outcomes for patients.
Gastro-oesophageal reflux and idiopathic pulmonary fibrosis: sorting the chicken and the egg by genetic link
Authors: Chad A. Newton, Imre Noth, Ganesh Raghu
Journal: European Respiratory Journal (2023)

Idiopathic pulmonary fibrosis (IPF) is a devastating condition that confers substantial morbidity and significantly reduces lifespan. Because of this, investigators have searched for modifiable risk factors to reduce the burden of IPF. While the aetiological holy grail for IPF remains elusive, there is mounting evidence that prevalent lung injuries on a background of genetic susceptibility culminate in this rare and "idiopathic" disease. Gastro-oesophageal reflux may be one of these prevalent lung injuries that culminate in lung fibrosis. In preclinical models, gastric acid aspiration into the lungs can trigger an inflammatory response and induce expression of transforming growth factor-β, resulting in epithelial–mesenchymal transition and interstitial collagen deposition [1–4]. Genetic factors predispose for gastro-oesophageal reflux and idiopathic pulmonary fibrosis <https://bit.ly/3utIoEs>
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background
Authors: Andrew Constantine, Konstantinos Dimopoulos, Christian Gerges, Irene M. Lang
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>Adult-onset peripheral pulmonary artery stenosis has a strong genetic basis, systemic involvement, and unclear pathogenesis. Both in terms of classification and management, it straddles the boundary between group 4 and 5 pulmonary hypertension.</b>https://bit.ly/3R77JMn
Having new eyes: MRI for visualisation of pulmonary vascular disease and prediction of bronchopulmonary dysplasia severity
Authors: Jennifer M.S. Sucre, David B. Frank
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>New work demonstrates the feasibility of using non-sedated cardiac MRI to identify and predict pulmonary vascular disease in infants with bronchopulmonary dysplasia, with significant promise as a noninvasive, predictive measure</b> https://bit.ly/411Xai6
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease
Authors: Stephanie Thee, Miquel Ekkelenkamp, Anand Shah
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>The AMR-Lung CRC works to understand the role of antimicrobial resistance (AMR) in chronic lung infections by bringing together stakeholders and developing a research agenda with the goal of improving the diagnosis and treatment of AMR lung infections</b>https://bit.ly/49SxaK8
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow
Authors: Markus Weckmann, Karosham Diren Reddy
Journal: European Respiratory Journal (2023)

<h3>Tweetable abstract</h3> <b>In general, epigenetic research data is underrepresenting highly vulnerable groups (<i>e.g</i>. children), whose exposome (<i>e.g</i>. socioeconomic, cultural background) and its contribution to disease endotypes is key to personalised medicine</b>https://bit.ly/3QZ4DKi
Influenza vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Geriatrics and Gerontology, and the Study Group of Geriatrics of the Portuguese Society of Internal Medicine
Authors: F. Froes, A. Timóteo, B. Almeida, J.F. Raposo, J. Oliveira, M. Carrageta, S. Duque, A. Morais
Journal: Pulmonology (2023)

Influenza affects millions of people worldwide each year and can lead to severe complications, hospitalizations, and even death, especially among vulnerable populations such as older adults and those with chronic medical conditions. Annual vaccination is considered the most effective measure for preventing influenza and its complications. Despite the widespread availability of influenza vaccines, however, vaccination coverage rates remain suboptimal in several countries. Based on the latest scientific evidence and expert opinions on influenza vaccination in older people and patients with chronic disease, the Portuguese Society of Pulmonology (SPP), the Portuguese Society of Diabetology (SPD), the Portuguese Society of Cardiology (SPC), the Portuguese Society of Geriatrics and Gerontology (SPGG), the Study Group of Geriatrics of the Portuguese Society of Internal Medicine (NEGERMI-SPMI), and the Portuguese Society of Infectious Diseases and Clinical Microbiology (SPDIMC) discussed best practices for promoting vaccination uptake and coverage and drew up several recommendations to mitigate the impact of influenza. These recommendations focus on the efficacy and safety of available vaccines; the impact of influenza vaccination on older adults; patients with chronic medical conditions, namely cardiac and respiratory conditions, diabetes, and immunosuppressive diseases; and health care professionals, optimal vaccination timing, and strategies to increase vaccination uptake and coverage. The resulting position paper highlights the critical role that vaccinations play in promoting public health, raising awareness, and encouraging more people to get vaccinated.
D1 and D2 medium spiny neurons in the nucleus accumbens core have distinct and valence-independent roles in learning
Authors: Jennifer E. Zachry, Munir Gunes Kutlu, Hye Jean Yoon, Michael Z. Leonard, Maxime Chevée, Dev D. Patel, Anthony Gaidici, Veronika Kondev, Kimberly C. Thibeault, Rishik Bethi, Jennifer Tat, Patrick R. Melugin, Atagun U. Isiktas, Max E. Joffe, Denise J. Cai, P. Jeffrey Conn, Brad A. Grueter, Erin S. Calipari
Journal: Neuron (2023)
Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth
Authors: Aida Rashidi, Leah K. Billingham, Andrew Zolp, Tzu-yi Chia, Caylee Silvers, Joshua L. Katz, Cheol H. Park, Suzi Delay, Lauren Boland, Yuheng Geng, Steven M. Markwell, Crismita Dmello, Victor A. Arrieta, Kaylee Zilinger, Irene M. Jacob, Aurora Lopez-Rosas, David Hou, Brandyn Castro, Alicia M. Steffens, Kathleen McCortney, Jordain P. Walshon, Mariah S. Flowers, Hanchen Lin, Hanxiang Wang, Junfei Zhao, Adam Sonabend, Peng Zhang, Atique U. Ahmed, Daniel J. Brat, Dieter H. Heiland, Catalina Lee-Chang, Maciej S. Lesniak, Navdeep S. Chandel, Jason Miska
Journal: Cell Metabolism (2023)
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
Authors: Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F. Contreras, Caroline Duault, Priyanka B. Subrahmanyam, Warren Reynolds, Norma A. Gutierrez, Reema Baskar, Catherine J. Wu, Franziska Michor, Jennifer Altreuter, Yang Liu, Aashna Jhaveri, Vandon Duong, Hima Anbunathan, Claire Ong, Hua Zhang, Radim Moravec, Joyce Yu, Roshni Biswas, Stephen Van Nostrand, James Lindsay, Mina Pichavant, Elena Sotillo, Donna Bernstein, Amanda Carbonell, Joanne Derdak, Jacquelyn Klicka-Skeels, Julia E. Segal, Eva Dombi, Stephanie A. Harmon, Baris Turkbey, Bita Sahaf, Sean Bendall, Holden Maecker, Steven L. Highfill, David Stroncek, John Glod, Melinda Merchant, Catherine C. Hedrick, Crystal L. Mackall, Sneha Ramakrishna, Rosandra N. Kaplan
Journal: Cancer Cell (2023)
B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis
Authors: Can Ulutekin, Edoardo Galli, Bettina Schreiner, Mohsen Khademi, Ilaria Callegari, Fredrik Piehl, Nicholas Sanderson, Daniel Kirschenbaum, Sarah Mundt, Massimo Filippi, Roberto Furlan, Tomas Olsson, Tobias Derfuss, Florian Ingelfinger, Burkhard Becher
Journal: Cell Reports Medicine (2023)

Multiple sclerosis is a chronic inflammatory disease of the central nervous system. Whereas T cells are likely the main drivers of disease development, the striking efficacy of B cell-depleting therapies (BCDTs) underscore B cells' involvement in disease progression. How B cells contribute to multiple sclerosis (MS) pathogenesis—and consequently the precise mechanism of action of BCDTs—remains elusive. Here, we analyze the impact of BCDTs on the immune landscape in patients with MS using high-dimensional single-cell immunophenotyping. Algorithm-guided analysis reveals a decrease in circulating T follicular helper-like (Tfh-like) cells alongside increases in CD27 expression in memory T helper cells and Tfh-like cells. Elevated CD27 indicates disrupted CD27/CD70 signaling, as sustained CD27 activation in T cells leads to its cleavage. Immunohistological analysis shows CD70-expressing B cells at MS lesion sites. These results suggest that the efficacy of BCDTs may partly hinge upon the disruption of Th cell and B cell interactions.
Microbiome preterm birth DREAM challenge: Crowdsourcing machine learning approaches to advance preterm birth research
Authors: Jonathan L. Golob, Tomiko T. Oskotsky, Alice S. Tang, Alennie Roldan, Verena Chung, Connie W.Y. Ha, Ronald J. Wong, Kaitlin J. Flynn, Antonio Parraga-Leo, Camilla Wibrand, Samuel S. Minot, Boris Oskotsky, Gaia Andreoletti, Idit Kosti, Julie Bletz, Amber Nelson, Jifan Gao, Zhoujingpeng Wei, Guanhua Chen, Zheng-Zheng Tang, Pierfrancesco Novielli, Donato Romano, Ester Pantaleo, Nicola Amoroso, Alfonso Monaco, Mirco Vacca, Maria De Angelis, Roberto Bellotti, Sabina Tangaro, Abigail Kuntzleman, Isaac Bigcraft, Stephen Techtmann, Daehun Bae, Eunyoung Kim, Jongbum Jeon, Soobok Joe, Kevin R. Theis, Sherrianne Ng, Yun S. Lee, Patricia Diaz-Gimeno, Phillip R. Bennett, David A. MacIntyre, Gustavo Stolovitzky, Susan V. Lynch, Jake Albrecht, Nardhy Gomez-Lopez, Roberto Romero, David K. Stevenson, Nima Aghaeepour, Adi L. Tarca, James C. Costello, Marina Sirota
Journal: Cell Reports Medicine (2023)

Every year, 11% of infants are born preterm with significant health consequences, with the vaginal microbiome a risk factor for preterm birth. We crowdsource models to predict (1) preterm birth (PTB; <37 weeks) or (2) early preterm birth (ePTB; <32 weeks) from 9 vaginal microbiome studies representing 3,578 samples from 1,268 pregnant individuals, aggregated from public raw data via phylogenetic harmonization. The predictive models are validated on two independent unpublished datasets representing 331 samples from 148 pregnant individuals. The top-performing models (among 148 and 121 submissions from 318 teams) achieve area under the receiver operator characteristic (AUROC) curve scores of 0.69 and 0.87 predicting PTB and ePTB, respectively. Alpha diversity, VALENCIA community state types, and composition are important features in the top-performing models, most of which are tree-based methods. This work is a model for translation of microbiome data into clinically relevant predictive models and to better understand preterm birth.
A facile boronophenylalanine modified polydopamine dual drug-loaded nanoparticles for enhanced anti-tumor immune response in hepatocellular carcinoma comprehensive treatment
Authors: Fan Yang, Liqun Dai, Kun Shi, Qingya Liu, Meng Pan, Dong Mo, Hanzhi Deng, Liping Yuan, Yi Lu, Lili Pan, Tingyu Yang, Zhiyong Qian
Journal: Biomaterials (2023)
RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity
Authors: Xin Li, Kai Jin, Tzu-Chun Cheng, You-Cheng Liao, Wen-Jui Lee, Abhjeet S. Bhullar, Li-Ching Chen, Piotr Rychahou, Mitch A. Phelps, Yuan Soon Ho, Peixuan Guo
Journal: Biomaterials (2023)
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
Authors: Sara Cajander, Matthijs Kox, Brendon P Scicluna, Markus A Weigand, Raquel Almansa Mora, Stefanie B Flohé, Ignacio Martin-Loeches, Gunnar Lachmann, Massimo Girardis, Alberto Garcia-Salido, Frank M Brunkhorst, Michael Bauer, Antoni Torres, Andrea Cossarizza, Guillaume Monneret, Jean-Marc Cavaillon, Manu Shankar-Hari, Evangelos J Giamarellos-Bourboulis, Martin Sebastian Winkler, Tomasz Skirecki, Marcin Osuchowski, Ignacio Rubio, Jesus F Bermejo-Martin, Joerg C Schefold, Fabienne Venet
Journal: The Lancet Respiratory Medicine (2023)